Unit­ed Ther­a­peu­tics sues FDA over han­dling of Liq­uidia’s new drug ap­pli­ca­tion for tre­pros­tinil

Unit­ed Ther­a­peu­tics is su­ing the FDA over how the agency han­dled Liq­uidia’s new drug ap­pli­ca­tion for its ver­sion of tre­pros­tinil, an in­haled pow­der that treats pul­monary ar­te­r­i­al hy­per­ten­sion.

In a 49-page com­plaint filed Tues­day in the US Dis­trict Court for DC, Unit­ed makes the case that the FDA mis­han­dled a new drug ap­pli­ca­tion for tre­pros­tinil filed by its com­peti­tor Liq­uidia, which Liq­uidia amend­ed while it was still pend­ing to in­clude an in­di­ca­tion for pul­monary hy­per­ten­sion as­so­ci­at­ed with in­ter­sti­tial lung dis­ease (PH-ILD).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER